CN112195169A - 包含重组人凝血因子Xa蛋白的异质性群体的组合物 - Google Patents

包含重组人凝血因子Xa蛋白的异质性群体的组合物 Download PDF

Info

Publication number
CN112195169A
CN112195169A CN202011112690.1A CN202011112690A CN112195169A CN 112195169 A CN112195169 A CN 112195169A CN 202011112690 A CN202011112690 A CN 202011112690A CN 112195169 A CN112195169 A CN 112195169A
Authority
CN
China
Prior art keywords
seq
heavy chain
amino acids
light
protein sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011112690.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·扬科斯基
K·A·约翰逊
W·C·皮阿森扎
J·C·罗斯
M·沙马施金
P·J·夏泊
M·B·斯威泽
S·B·韦斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN112195169A publication Critical patent/CN112195169A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
CN202011112690.1A 2013-09-24 2014-09-16 包含重组人凝血因子Xa蛋白的异质性群体的组合物 Pending CN112195169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
US61/881,834 2013-09-24
CN201480052212.2A CN105579468A (zh) 2013-09-24 2014-09-16 包含重组人凝血因子Xa蛋白的异质性群体的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480052212.2A Division CN105579468A (zh) 2013-09-24 2014-09-16 包含重组人凝血因子Xa蛋白的异质性群体的组合物

Publications (1)

Publication Number Publication Date
CN112195169A true CN112195169A (zh) 2021-01-08

Family

ID=51844797

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011112690.1A Pending CN112195169A (zh) 2013-09-24 2014-09-16 包含重组人凝血因子Xa蛋白的异质性群体的组合物
CN201480052212.2A Pending CN105579468A (zh) 2013-09-24 2014-09-16 包含重组人凝血因子Xa蛋白的异质性群体的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480052212.2A Pending CN105579468A (zh) 2013-09-24 2014-09-16 包含重组人凝血因子Xa蛋白的异质性群体的组合物

Country Status (19)

Country Link
US (3) US9757434B2 (https=)
EP (1) EP3049434A1 (https=)
JP (1) JP6429885B2 (https=)
KR (1) KR101988705B1 (https=)
CN (2) CN112195169A (https=)
AR (1) AR097732A1 (https=)
AU (1) AU2014326257B2 (https=)
BR (1) BR112016005899A8 (https=)
CA (1) CA2924981C (https=)
HK (1) HK1218760A1 (https=)
IL (2) IL244258A0 (https=)
MX (1) MX373466B (https=)
MY (1) MY173548A (https=)
PE (1) PE20160877A1 (https=)
RU (1) RU2648144C2 (https=)
SA (1) SA516370751B1 (https=)
SG (1) SG11201601221XA (https=)
TW (1) TWI631134B (https=)
WO (1) WO2015044836A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802188A (zh) * 2007-09-28 2010-08-11 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
CN102316893A (zh) * 2008-11-14 2012-01-11 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
TW201217527A (en) * 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
BR112016014617A2 (pt) 2014-01-24 2017-09-19 Pfizer Variante do fator xa (fxa) e usos da referida variante

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802188A (zh) * 2007-09-28 2010-08-11 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
CN102559644A (zh) * 2007-09-28 2012-07-11 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
CN102316893A (zh) * 2008-11-14 2012-01-11 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LACRAMIOARA IVANCIU: "A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia", NATURE BIOTECHNOLOGY, vol. 29, no. 11, pages 1028, XP055111224, DOI: 10.1038/nbt.1995 *

Also Published As

Publication number Publication date
RU2016108608A (ru) 2017-10-26
JP6429885B2 (ja) 2018-11-28
WO2015044836A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22
US20210106658A1 (en) 2021-04-15
BR112016005899A8 (pt) 2018-02-06
AU2014326257A1 (en) 2016-03-10
TWI631134B (zh) 2018-08-01
MY173548A (en) 2020-02-04
SA516370751B1 (ar) 2018-04-05
US20150182604A1 (en) 2015-07-02
IL279396A (en) 2021-01-31
MX373466B (es) 2020-05-25
TW201524996A (zh) 2015-07-01
HK1218760A1 (zh) 2017-03-10
PE20160877A1 (es) 2016-09-11
US10660946B2 (en) 2020-05-26
US9757434B2 (en) 2017-09-12
CN105579468A (zh) 2016-05-11
EP3049434A1 (en) 2016-08-03
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
SG11201601221XA (en) 2016-04-28
BR112016005899A2 (pt) 2017-09-26
JP2016535071A (ja) 2016-11-10
RU2648144C2 (ru) 2018-03-22
AU2014326257B2 (en) 2017-08-10
CA2924981A1 (en) 2015-04-02
KR101988705B1 (ko) 2019-06-12
IL244258A0 (en) 2016-04-21
AR097732A1 (es) 2016-04-13
CA2924981C (en) 2020-03-31

Similar Documents

Publication Publication Date Title
US20210106658A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
US20250230426A1 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2108046B1 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
US9896677B2 (en) Purification of blood coagulation factors
KR20150026024A (ko) 인간 혈액응고 7인자 유도체의 대량 생산 방법
AU2014202989B2 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US20190264188A1 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2016238889B2 (en) Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
HK1178048A (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
WO2017025566A1 (en) Improved recombinant factor vii

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210108